Current Oral Antiplatelets: Focus Update on Prasugrel

John, Jinu; Koshy, Santosh

doi:10.3122/jabfm.2012.03.100270

Cited by 14 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinic efficacy has been evaluated in the TRITON-TIMI 38 study where we can see the efficacy of prasugrel and ASA compared to clopidogrel and ASA. The results of this study demonstrated than the incidence of cardiovascular death, AMI, and stroke are less, but we observe a major tendency of bleeding, including fatal ending (7), above all in patients older than 75 yeas old, weight less than 60 kilograms and patients with previous stroke or TIA (4) and/or coronary by pass surgery (6), so we must avoid using this drug in this patients (5). …”

Section: Bibliographic Review Antiplatelet Drugsmentioning

confidence: 77%

“…There are different studies that prove the efficacy of the treatment with the classical antiplatelets alone or dual antiplatelets therapy (3,4). They has a residual risk of ischemic diseases, high risk of bleeding and a variable antiplatelet effect, so it has done that scientist look for a new antiplatelets drugs mainly in the group of receptors p2y12 of the ADP inhibitors and in another groups.…”

Section: Bibliographic Review Antiplatelet Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical diseases with thrombotic risk and their pharmacologycal treatment: How they change the therapeutic attitude in dental treatments

Martínez-López

Sánchez²,

Jj³

et al. 2013

Med Oral

View full text Add to dashboard Cite

The new antiplatelets and anticoagulant drugs have been recently introduced in the daily medical practices for the control of thromboembolism associated with different diseases. The dental assistance of these patients forces us to know these drugs, understand their action mechanisms and try to decrease the risks that entail ours actions in these patients, making a thorough analysis of the risk of bleeding that is going to be related to our medical intervention, as well as the use of all the control measures of the hemorrhage from our knowledge with these patients, and to be prudent. The communication with the medical specialist that supervises these patients must be maxim, being necessary to make clinic trials for establishing protocols or guides of the handling with these patients during the odontological treatment. Key words:Antiplatelet drugs, anticoagulants drugs, new/classic, thrombotic risk, hemorrhagic risk, dental treatment, caution.

show abstract

Section: Bibliographic Review Antiplatelet Drugsmentioning

confidence: 77%

Section: Bibliographic Review Antiplatelet Drugsmentioning

confidence: 99%

Clinical diseases with thrombotic risk and their pharmacologycal treatment: How they change the therapeutic attitude in dental treatments

Martínez-López

Sánchez²,

Jj³

et al. 2013

Med Oral

View full text Add to dashboard Cite

show abstract

“…2 Thus, this quality has made it a popular drug target for the treatment of anti-thrombosis. However, administering P2Y 12 receptor antagonists can potentially lead to several adverse reactions, [3][4][5] such as aplastic anemia, increased bleeding risk, and dyspnea. Therefore, since the protein's crystal structure was recently resolved, 6 there is an urgent need for the further design and discovery of more selective and secure antagonists for treatment application.…”

Section: Introductionmentioning

confidence: 98%

A combination of pharmacophore modeling, molecular docking, and virtual screening for P2Y₁₂ receptor antagonists from Chinese herbs

Liang-duo

Qiao

et al. 2015

Can. J. Chem.

View full text Add to dashboard Cite

P2Y 12 , a member of the G-protein-coupled receptors, is associated with abnormal platelet aggregation, a condition that contributes to thrombus formation. As receptor antagonists are effective solutions for anti-thrombus, the P2Y 12 receptor is a popular drug target. After the recent resolution of the P2Y 12 receptor's crystal structure, pharmacophore modeling and docking were combined to discover potential natural antagonists. Various approaches were used for the validation of the pharmacophore models and the optimization of docking algorithms. Hypo18, which was generated by 24 known antagonists, was determined to be the best hypothesis and is comprised of one ring aromatic, one hydrogen bond acceptor, one exclude volume, and three hydrophobic features. Hypo18 was thus utilized to screen TCMD (version 2009) to identify any potential active compounds, which then resulted in a hit list of 121 compounds with drug-likeness analysis. In addition, docking was used to refine the pharmacophorebased screening results as a cross-linking method. Then, the top 20 compounds with high docking scores were reserved. This paper provides a reliable source for discovering natural P2Y 12 receptor antagonists from traditional Chinese herbs.Résumé : Le récepteur P2Y 12 , membre de la famille des récepteurs couplés aux protéines G, est associé à des anomalies de l'agrégation plaquettaire, un trouble qui contribue à la formation de thrombus. Comme les antagonistes du récepteur P2Y 12 représentent des solutions anti-thrombus efficaces, ce récepteur constitue une cible thérapeutique privilégiée. À la suite de la récente résolution de la structure cristalline du récepteur P2Y 12 , des études de modélisation et de simulation d'amarrage du pharmacophore ont été combinées en vue de découvrir d'éventuels antagonistes naturels. Diverses approches dont le but était de valider les modèles moléculaires du pharmacophore et d'optimiser les algorithmes d'amarrage ont été utilisées. Le modèle Hypo18, généré à partir de 24 antagonistes connus, a été retenu comme la meilleure hypothèse et comprend un noyau aromatique, un accepteur de liaison hydrogène, un volume exclu et trois surfaces hydrophobes. Nous avons donc utilisé le modèle Hypo18 aux fins du criblage de la base de données de la médecine traditionnelle chinoise, la TCMD (version 2009), dans le but de trouver d'éventuels composés actifs. Cette opération a permis de dresser une liste de 121 composés dont le profil présente une possible activité pharmacologique. Puis, les résultats de criblage du pharmacophore ont été raffinés au moyen de la simulation d'amarrage moléculaire utilisée comme méthode de réticulation. Par la suite, les 20 composés présentant les meilleurs résultats d'arrimage ont été retenus. Cet article constitue une source fiable dans le processus de recherche d'antagonistes naturels du récepteur P2Y 12 à partir de plantes médicinales chinoises. [Traduit par la Rédaction] Mots-clés : antagonistes du récepteur P2Y12, modélisation du pharmacophore, amarrage, criblage virtuel, médecin...

show abstract

“…Thiophene is a commonly used core structure in pharmaceutical drugs (Figure 1). 1 Thiophene-containing molecules are known to exhibit antimicrobial, 2 non-steroidal anti-inflammatory, 3 platelet inhibitory, 4 antitumor, 5 and antiviral activity. 6 In addition, thiophenes are also used in polymers and materials that have a potential application in the area of organic field-effect transistors (OFETs) and organic light-emitting diodes (OLEDs).…”

mentioning

confidence: 99%

Green synthesis of halogenated thiophenes, selenophenes and benzo[b]selenophenes using sodium halides as a source of electrophilic halogens

Kesharwani

Giraudy

Morgan

et al. 2017

Tetrahedron Letters

View full text Add to dashboard Cite

Herein, we report the first synthesis of chlorinated benzo[b]selenophenes via environmentally friendly electrophilic chlorocyclization reaction using “table salt” as a source of “electrophilic chlorine” and ethanol as a solvent. In addition, the synthesis of diverse halogenated heterocycles, including 3-chloro, 3-bromo and 3-iodo thiophenes, selenophenes, and benzo[b]selenophenes was successfully accomplished under the same environmentally benign reaction conditions. This methodology has several advantages over other previously reported reactions as it employs simple starting compounds, an environmentally friendly solvent, ethanol, and non-toxic inorganic reagents under mild reaction conditions, resulting in the high product yields.

show abstract

Current Oral Antiplatelets: Focus Update on Prasugrel

Cited by 14 publications

References 30 publications

Clinical diseases with thrombotic risk and their pharmacologycal treatment: How they change the therapeutic attitude in dental treatments

Clinical diseases with thrombotic risk and their pharmacologycal treatment: How they change the therapeutic attitude in dental treatments

A combination of pharmacophore modeling, molecular docking, and virtual screening for P2Y₁₂ receptor antagonists from Chinese herbs

Green synthesis of halogenated thiophenes, selenophenes and benzo[b]selenophenes using sodium halides as a source of electrophilic halogens

Contact Info

Product

Resources

About

Current Oral Antiplatelets: Focus Update on Prasugrel

Cited by 14 publications

References 30 publications

Clinical diseases with thrombotic risk and their pharmacologycal treatment: How they change the therapeutic attitude in dental treatments

Clinical diseases with thrombotic risk and their pharmacologycal treatment: How they change the therapeutic attitude in dental treatments

A combination of pharmacophore modeling, molecular docking, and virtual screening for P2Y12 receptor antagonists from Chinese herbs

Green synthesis of halogenated thiophenes, selenophenes and benzo[b]selenophenes using sodium halides as a source of electrophilic halogens

Contact Info

Product

Resources

About

A combination of pharmacophore modeling, molecular docking, and virtual screening for P2Y₁₂ receptor antagonists from Chinese herbs